SHMLF (SHL Telemedicine) 1-Year Sharpe Ratio: -87.39 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHMLF SHL Telemedicine Ltd SHMLF
52 GF Score
Price $4.84
GF Value $12.26
! 3 Warning Signs
View Full Analysis

What is SHL Telemedicine 1-Year Sharpe Ratio?

SHL Telemedicine SHMLF 52 1-Year Sharpe Ratio is -87.39 as of Jul. 20, 2026. GuruFocus rates SHMLF with a GF Score™ of 52/100 and a GF Value™ of $12.26. The stock has 3 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-20), SHL Telemedicine's 1-Year Sharpe Ratio is -87.39.

SHL Telemedicine  (OTCPK:SHMLF) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

SHL Telemedicine 1-Year Sharpe Ratio Related Terms

SHMLF vs VEEV, BTSG, TEM: 1-Year Sharpe Ratio Comparison

For the Health Information Services subindustry, SHL Telemedicine's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SHL Telemedicine 1-Year Sharpe Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where SHL Telemedicine's 1-Year Sharpe Ratio falls into.


SHMLF
52GF Score
SHL Telemedicine Ltd SHMLF
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SHL Telemedicine 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -87.39 mean?
SHL Telemedicine (SHMLF) has a 1-Year Sharpe Ratio of -87.39 as of Jul. 20, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for SHL Telemedicine and its competitors.
Is SHL Telemedicine's 1-Year Sharpe Ratio too high?
SHL Telemedicine's current 1-Year Sharpe Ratio is -87.39. Overall, SHL Telemedicine has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's 1-Year Sharpe Ratio compare to VEEV and BTSG?
SHL Telemedicine's 1-Year Sharpe Ratio of -87.39 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Healthcare Providers & Services company?
A good 1-Year Sharpe Ratio depends on the Healthcare Providers & Services industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for SHL Telemedicine and its competitors. SHL Telemedicine's current 1-Year Sharpe Ratio is -87.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current 1-Year Sharpe Ratio of -87.39. The stock's GF Value™ is $12.26, compared to a current price of $4.84 — trading 60.5% below its estimated fair value. The current 1-Year Sharpe Ratio is -87.39. SHL Telemedicine's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current 1-Year Sharpe Ratio is -87.39 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SHL Telemedicine (SHMLF) Overvalued in 2026?

Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued. The current stock price of $4.84 is trading 60.5% below its estimated GF Value™ of $12.26.

Key valuation signals for SHMLF:

  • 1-Year Sharpe Ratio: -87.39
  • GF Value™: $12.26 vs. price of $4.84 (60.5% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SHL Telemedicine Business Description

Other Exchanges 0QMX:UKSHLTN:Switzerland
Address 90 Yigal Alon Street, Tel Aviv, ISR, 67891
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
52GF Score

Get the complete analysis for SHMLF

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.84
Price
$12.26
GF Value